Satyajit Kosuri to Female
This is a "connection" page, showing publications Satyajit Kosuri has written about Female.
Connection Strength
0.125
-
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Nov; 23(11):2004-2011.
Score: 0.030
-
Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. Leuk Lymphoma. 2014 Mar; 55(3):476-7.
Score: 0.024
-
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. J Clin Invest. 2020 12 01; 130(12):6668-6676.
Score: 0.009
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.009
-
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.
Score: 0.009
-
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.
Score: 0.008
-
Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 01; 24(1):142-149.
Score: 0.008
-
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 01; 24(1):133-141.
Score: 0.008
-
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. J Clin Oncol. 2017 May 20; 35(15):1650-1659.
Score: 0.007
-
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leuk Lymphoma. 2017 08; 58(8):1823-1831.
Score: 0.007
-
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biol Blood Marrow Transplant. 2016 Feb; 22(2):258-267.
Score: 0.007